Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innospec (IOSP) Cash & Equivalents (2016 - 2025)

Innospec's Cash & Equivalents history spans 16 years, with the latest figure at $292.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 1.14% year-over-year to $292.5 million; the TTM value through Dec 2025 reached $292.5 million, up 1.14%, while the annual FY2025 figure was $292.5 million, 1.14% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $292.5 million at Innospec, up from $270.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $303.8 million in Q3 2024 and bottomed at $71.4 million in Q2 2022.
  • The 5-year median for Cash & Equivalents is $184.8 million (2023), against an average of $191.2 million.
  • The largest annual shift saw Cash & Equivalents decreased 24.36% in 2022 before it surged 132.35% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $141.8 million in 2021, then increased by 3.74% to $147.1 million in 2022, then skyrocketed by 38.48% to $203.7 million in 2023, then soared by 41.97% to $289.2 million in 2024, then rose by 1.14% to $292.5 million in 2025.
  • Per Business Quant, the three most recent readings for IOSP's Cash & Equivalents are $292.5 million (Q4 2025), $270.8 million (Q3 2025), and $266.6 million (Q2 2025).